Page 109 - 南京医科大学自然版

第45卷第1期 许杨悦，马 佩，束永前. 抗体偶联药物在肺癌靶向治疗中的临床研究进展［J］.
2025年1月 南京医科大学学报（自然科学版），2025，45（1）：98-104 ·103 ·

breast cancer［J］. Genes，2022，13（11）：2065 and overall survival in the U31402⁃A⁃U102 study of patri⁃
［9］ PETERS S，STAHEL R，BUBENDORF L，et al. Trastu⁃ tumab deruxtecan（HER3 ⁃ DXd） in EGFR ⁃ mutated
zumab emtansine（T ⁃ DM1）in patients with previously NSCLC［J］. Ann Oncol，2024，35（5）：437-447
treated HER2 ⁃ overexpressing metastatic non ⁃ small cell ［20］ SCHIPILLITI F M，DRITTONE D，MAZZUCA F，et al.
lung cancer：efficacy，safety，and biomarkers［J］. Clin Datopotamab deruxtecan：a novel antibody drug conju⁃
Cancer Res，2019，25（1）：64-72 gate for triple⁃negative breast cancer［J］. Heliyon，2024，
［10］LI B T，SHEN R L，BUONOCORE D，et al. Ado⁃trastu⁃ 10（7）：e28385
zumab emtansine for patients with HER2 ⁃ mutant lung ［21］ SHIMIZU T，SANDS J，YOH K，et al. First⁃in⁃human，
cancers：results from a phaseⅡbasket trial［J］. J Clin On⁃ phaseⅠdose⁃escalation and dose⁃expansion study of tro⁃
col，2018，36（24）：2532-2537 phoblast cell ⁃ surface antigen 2 ⁃ directed antibody ⁃ drug
［11］JEBBINK M，DE LANGEN A J，MONKHORST K，et al. conjugate datopotamab deruxtecan in non⁃small⁃cell lung
Trastuzumab⁃emtansine and osimertinib combination ther⁃ cancer：TROPION⁃PanTumor01［J］. J Clin Oncol，2023，
apy to target HER2 bypass track resistance in EGFR mu⁃ 41（29）：4678-4687
tation ⁃ positive NSCLC［J］. JTO Clin Res Rep，2023，4 ［22］ YOH K，GOTO Y，THOMAS M，et al. A randomized，
（4）：100481 phase 3 study of datopotamab deruxtecan（Dato⁃DXd；DS⁃
［12］AZAR I，ALKASSIS S，FUKUI J，et al. Spotlight on trastu⁃ 1062）versus docetaxel in previously treated advanced or
zumab deruxtecan（DS⁃8201，T⁃DXd）for HER2 mutation metastatic non ⁃ small cell lung cancer（NSCLC）without
positive non ⁃ small cell lung cancer［J］. Lung Cancer， actionable genomic alterations（TROPION⁃Lung01）［J］. J
2021，12：103-114 lin Oncol，2021，39（15_suppl）：TPS9127
［13］MEHTA G U，VELLANKI P J，REN Y，et al. FDA approv⁃ ［23］曾天星，田婵婵，赵明栋，等. 抗体偶联药物在非小细胞
al summary：fam⁃trastuzumab deruxtecan⁃nxki for unre⁃ 肺癌中的研究进展［J］. 临床肺科杂志，2024，29（5）：
sectable or metastatic non⁃small cell lung cancer with acti⁃ 785-791
vating HER2 mutations［J］. Oncologist，2024，29（8）： ZENG T X，TIAN C C，ZHAO M D，et al. Research prog⁃

667-671 ress of antibody⁃drug conjugates in non⁃small cell lung
［14］LI B T，SMIT E F，GOTO Y，et al. Trastuzumab deruxte⁃ cancer［J］. Journal of Clinical Pulmonary Medicine，2024，
can in HER2⁃mutant non⁃small⁃cell lung cancer［J］. N 29（5）：785-791
Engl J Med，2022，386（3）：241-251 ［24］PAZ⁃ARES L，AHN M J，LISBERG A E，et al. 1314MO
［15］ Interim results from the Phase Ⅱ DESTINY⁃Lung02 trial TROPION⁃Lung05：Datopotamab deruxtecan（Dato⁃DXd）
of trastuzumab deruxtecan supporting the recent acceler⁃ in previously treated non⁃small cell lung cancer（NSCLC）
ated approval revealed［EB/OL］.（2022-09-12）［2024- with actionable genomic alterations（AGAs）［J］. Ann On⁃
09-05］. https：//www.delveinsight.com/esmo⁃conference⁃ col，2023，34：S755-S756
2022/article/destiny⁃lung⁃02⁃enhertu ［25］LEVY B P，FELIP E，RECK M，et al. TROPION⁃Lung08：
［16］ LU Y S，SHIMIZU S，SAWAMURA R，et al. Population phaseⅢstudy of datopotamab deruxtecan plus pembroli⁃
pharmacokinetics of patritumab deruxtecan in patients zumab as first⁃line therapy for advanced NSCLC［J］. Fu⁃
with solid tumors［J］. J Clin Pharmacol，2023，63（1）：77- ture Oncol，2023，19（21）：1461-1472
90 ［26］GOLDENBERG D M，CARDILLO T M，GOVINDAN S V，
［17］JÄNNE P A，BAIK C，SU W C，et al. Efficacy and safety et al. Trop⁃2 is a novel target for solid cancer therapy with
of patritumab deruxtecan（HER3⁃DXd）in EGFR inhibitor⁃ sacituzumab govitecan（IMMU ⁃ 132），an antibody ⁃ drug
resistant，EGFR⁃mutated non⁃small cell lung cancer［J］. conjugate（ADC）［J］. Oncotarget，2015，6（26）：22496-
Cancer Discov，2022，12（1）：74-89 22512
［18］YU H A，GOTO Y，HAYASHI H，et al. HERTHENA ⁃ ［27］HEIST R S，GUARINO M J，MASTERS G，et al. Therapy
Lung01，a phaseⅡtrial of patritumab deruxtecan（HER3⁃ of advanced non⁃small⁃cell lung cancer with an SN⁃38⁃an⁃
DXd）in epidermal growth factor receptor⁃mutated non⁃ ti ⁃ trop ⁃ 2 drug conjugate，sacituzumab govitecan［J］. J
small⁃cell lung cancer after epidermal growth factor recep⁃ Clin Oncol，2017，35（24）：2790-2797
tor tyrosine kinase inhibitor therapy and platinum⁃based ［28］PAZ⁃ARES L G，JUAN⁃VIDAL O，MOUNTZIOS G S，et
chemotherapy［J］. J Clin Oncol，2023，41（35）：5363- al. Sacituzumab govitecan versus docetaxel for previously
5375 treated advanced or metastatic non⁃small cell lung cancer：
［19］YU H A，BAIK C，KIM D W，et al. Translational insights the randomized，open⁃label phaseⅢEVOKE⁃01 study［J］.